Coreline Soft Advances AI Software... "Adds Generative AI Features"

Coreline Soft announced on the 14th that it will integrate its proprietary artificial intelligence (AI) software (S/W) modularly through the new platform ‘CORE:XAI (Coreline: eXplainable Artificial Intelligence platform)’.

Coreline Soft plans to enhance the performance of existing products and improve the efficiency of new product development by integrating and managing the existing AI S/W ‘AVIEW’ series centered on CORE:XAI. After developing proprietary algorithms, it implemented image analysis S/W, obtained approvals from regulatory bodies worldwide including the U.S. FDA (Food and Drug Administration), and is currently supplying various AI technology-based products.

CORE:XAI will not only incorporate the technologies applied in AVIEW but also add predictive functions. Coreline Soft is developing predictive algorithms based on data accumulated during the use of the S/W, thereby advancing AI technology. Moreover, it has exclusive access to and utilization of data accumulated during the usage of AI S/W after supply. Based on this, implementation of AI predictive functions is also underway.

Coreline Soft plans to further advance AI technology and expand its application fields. The data used to build Coreline Soft’s AI S/W is more challenging to refine compared to general data. The company explains that since it has already successfully completed the commercialization of numerous AI S/W builds, developing AI solutions applicable to other industries is also facilitated.

Jinkook Kim, CEO of Coreline Soft, said, “We launched CORE:XAI to enhance the modularization and integrated management of our AI products, building on the advanced data refinement capabilities achieved through the recently launched CORE:ALAP.” He added, “We will strengthen AI technology based on segmentation and 3D modeling technologies applied within the S/W of CORE:XAI.”

He continued, “By centering on CORE:XAI, we will not only maximize competitiveness in the global market but also lay the groundwork to broaden the application scope of AI technology across industries in the future.”

Coreline Soft independently developed S/W that analyzes chest computed tomography (CT) images in three dimensions to simultaneously detect diseases such as lung cancer, chronic obstructive pulmonary disease (COPD), and coronary artery calcification at an early stage. The company has succeeded in supplying its proprietary S/W not only domestically but also to multiple countries in Europe including Germany, Italy, and the Netherlands, as well as to the Harbor-UCLA Medical Center at UCLA (University of California, Los Angeles) in the United States.